About Rpg Life Sciences Limited
Data last updated: 23 December 2025
Rpg Life Sciences Limited is a public limited company based in Mumbai, Maharashtra, India. It specialises in api manufacturers, a part of the broader pharmaceuticals sector. Incorporated on 29 March 2007, the company has been in operation for over 19 years.
Registered with ROC Mumbai under CIN L24232MH2007PLC169354. Listed on BSE: 532983 and NSE: RPGLIFE.
Capital: an authorised share capital of ₹15 Cr and a paid-up capital of ₹13.23 Cr. Formerly known as Rpg Pharmaceuticals Limited. It is led by directors including Sachin Rajkumar Nandgaonkar and Vasundhara Apoorva Patni.
Last AGM: 16 July 2025. Financial statements filed for year ended 31 March 2025. Office: Rpg House 463 Dr. Annie Besant Road Worli, Mumbai, Maharashtra, India – 400030.
As per the financials filed for FY 2025, the company reported a revenue of ₹666.11 Cr, a growth of 13% compared to the previous year.
The company has a workforce of approximately 1,197 employees as per the latest available data.
The company is associated with 1 brand - Rpg Life Sciences. As per MCA filings, the company has open charges of ₹65.92 Cr and satisfied charges of ₹71.07 Cr on record.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website rpglifesciences.com.
-
Email*****@*****.com
-
Telephone+91-****-******
-
Website
-
Social Media
-
Registered AddressRpg House 463 Dr. Annie Besant Road Worli, Mumbai, Maharashtra, India – 400030
-
IndustryPharma, API Manufacturers, Drug Formulation & Development
- Historical Financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Litigation, compliance and MCA filings
- PDF report delivered after checkout
CIN History of Rpg Life Sciences Limited
Rpg Life Sciences Limited has one previous CIN (Corporate Identification Number): U24232MH2007PLC169354. The current CIN is L24232MH2007PLC169354, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| L24232MH2007PLC169354 | Current |
| U24232MH2007PLC169354 | Previous |
Associated Brands with Rpg Life Sciences Limited
Rpg Life Sciences Limited operates one associated brand: RPG Life Sciences. These brands represent Rpg Life Sciences Limited's diversified market presence and brand portfolio.
| Brand | Description | Website |
|---|---|---|
| Generics and APIs are manufactured by RPG Life Sciences. | rpglifesciences.com |
Business Activity of Rpg Life Sciences Limited
Rpg Life Sciences Limited is engaged in the principal business activity of manufacturing, with detailed activities including chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products | ********* |
Auditor Details of Rpg Life Sciences Limited
Rpg Life Sciences Limited is audited by M/s SRBC & Co LLP (ICAI peer reviewed, certificate valid till 2029-02-28) for the financial year 2026, as reported in its NSE exchange filings. The statutory auditor is responsible for expressing an independent opinion on whether the financial statements present a true and fair view in accordance with applicable accounting standards.
| Name | Financial year | Audit opinion |
|---|---|---|
| M/s SRBC & Co LLP (ICAI peer reviewed, certificate valid till 2029-02-28) | FY 2026 | Declaration of unmodified opinion |
Board of Directors of Rpg Life Sciences Limited
Rpg Life Sciences Limited is currently managed by 15 directors, with 31 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Sachin Rajkumar Nandgaonkar | Director | 23 Jan 2015 | 11 Years 5 Months | Current |
|
Vasundhara Apoorva Patni
Also directs:
Prerak Management Consultancy Services Llp, Central Expressways Construction Llp, Brickstone Real Estate Llp and 3 more
|
Director | 28 Apr 2025 | 1 Years 2 Months | Current |
| Rajesh Ramesh Shirambekar | Nodal Officer | 28 Aug 2019 | 6 Years 10 Months | Current |
| Hiten Kantilal Kotak | Additional Director | 30 Apr 2024 | 2 Years 2 Months | Current |
|
Anilkumar Matai
Also directs:
Organisation Of Pharmaceutical Producers Of India
|
Additional Director | 30 Apr 2024 | 2 Years 2 Months | Current |
|
Rajat Bhargava
Also directs:
Harrisons Malayalam Ltd, Rpg Active Pharma Limited, Spencer International Hotels Limited and 2 more
|
Director | 25 Jan 2021 | 5 Years 5 Months | Current |
Financials of Rpg Life Sciences Limited FY 2026 filings available
Rpg Life Sciences Limited reported revenue of ₹707.52 Cr (up ) for FY 2026. Profit growth despite declining revenue indicates effective cost management and margin discipline.
| Metrics | FY 2026 |
|---|---|
| Revenue from Operations | ₹707.52 Cr |
| Other Income | ₹25.58 Cr |
| Total Income | ₹733.1 Cr |
| Cost of Materials Consumed | ₹135.98 Cr |
| Purchases of Stock-in-Trade | ₹138.1 Cr |
| Changes in Inventories | -₹21.99 Cr |
| Employee Benefit Expense | ₹141.48 Cr |
| Finance Costs | ₹89 Lakh |
| Depreciation & Amortisation | ₹21.48 Cr |
| Other Expenses | ₹166.86 Cr |
| Total Expenses | ₹582.8 Cr |
| Profit Before Exceptional Items & Tax | ₹150.3 Cr |
| Exceptional Items | ₹3.9 Cr |
| Profit Before Tax | ₹154.2 Cr |
| Total Tax Expense | ₹39.03 Cr |
| Net Profit | ₹115.17 Cr |
| Other Comprehensive Income | -₹64 Lakh |
| Total Comprehensive Income | ₹114.53 Cr |
| EBITDA (computed) | ₹172.67 Cr |
| Basic EPS | ₹18.08 |
| Diluted EPS | ₹0.00 |
| Metrics | FY 2026 |
|---|---|
| Total Assets | ₹793.15 Cr |
| Non-current Assets | ₹228.4 Cr |
| Current Assets | ₹564.75 Cr |
| Property, Plant & Equipment | ₹191.7 Cr |
| Inventories | ₹123.84 Cr |
| Trade Receivables | ₹116.68 Cr |
| Cash & Equivalents | ₹150.46 Cr |
| Equity (Net Worth) | ₹605.38 Cr |
| Equity Share Capital | ₹13.23 Cr |
| Borrowings (Non-current) | ₹13.33 Cr |
| Borrowings (Current) | ₹6.67 Cr |
| Total Debt (computed) | ₹20 Cr |
| Current Liabilities | ₹160.53 Cr |
| Total Liabilities | ₹187.77 Cr |
| Metrics | FY 2026 |
|---|---|
| Operating Cash Flow | ₹56.5 Cr |
| Investing Cash Flow | ₹85.84 Cr |
| Financing Cash Flow | -₹20.58 Cr |
| Capital Expenditure | ₹65.36 Cr |
| Free Cash Flow (computed) | -₹8.86 Cr |
| Dividends Paid | ₹39.69 Cr |
| Net Change in Cash | ₹121.76 Cr |
| Metrics | Q4 FY26 | Q3 FY26 |
|---|---|---|
| Revenue from Operations | ₹176.89 Cr | ₹180.03 Cr |
| Other Income | ₹12.4 Cr | ₹3.41 Cr |
| Total Income | ₹189.29 Cr | ₹183.44 Cr |
| Cost of Materials Consumed | ₹36.43 Cr | ₹34.79 Cr |
| Purchases of Stock-in-Trade | ₹22.63 Cr | ₹43.63 Cr |
| Changes in Inventories | ₹1.53 Cr | -₹13.52 Cr |
| Employee Benefit Expense | ₹36.3 Cr | ₹35.32 Cr |
| Finance Costs | ₹39 Lakh | ₹25 Lakh |
| Depreciation & Amortisation | ₹5.74 Cr | ₹5.38 Cr |
| Other Expenses | ₹47.17 Cr | ₹40.05 Cr |
| Total Expenses | ₹150.19 Cr | ₹145.9 Cr |
| Profit Before Exceptional Items & Tax | ₹39.1 Cr | ₹37.54 Cr |
| Exceptional Items | ₹1.1 Cr | -₹8.42 Cr |
| Profit Before Tax | ₹40.2 Cr | ₹29.12 Cr |
| Total Tax Expense | ₹10.3 Cr | ₹6.99 Cr |
| Net Profit | ₹29.9 Cr | ₹22.13 Cr |
| attributable to Owners | - | ₹0 |
| attributable to NCI | - | ₹0 |
| Other Comprehensive Income | ₹8 Lakh | -₹68 Lakh |
| Total Comprehensive Income | ₹29.98 Cr | ₹21.45 Cr |
| EBITDA (computed) | ₹45.23 Cr | ₹43.17 Cr |
| Basic EPS | ₹18.08 | ₹13.38 |
| Diluted EPS | ₹0.00 | ₹0.00 |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹707.52 Cr | ₹653.43 Cr | ₹582.05 Cr | ₹512.81 Cr | ₹440.16 Cr | ₹389.14 Cr | ₹375.57 Cr |
| Other Income | ₹25.54 Cr | ₹12.68 Cr | ₹7.21 Cr | ₹4.8 Cr | ₹2.99 Cr | ₹91 Lakh | ₹73 Lakh |
| Total Income | ₹733.06 Cr | ₹666.11 Cr | ₹589.26 Cr | ₹517.61 Cr | ₹443.15 Cr | ₹390.05 Cr | ₹376.3 Cr |
| Cost of Materials Consumed | ₹135.98 Cr | ₹110.26 Cr | ₹120.65 Cr | ₹86.12 Cr | ₹88.13 Cr | ₹85.75 Cr | ₹75.13 Cr |
| Purchases of Stock-in-Trade | ₹138.1 Cr | ₹95.14 Cr | ₹61.18 Cr | ₹92.05 Cr | ₹78.9 Cr | ₹50.36 Cr | ₹58.61 Cr |
| Changes in Inventories | -₹21.99 Cr | ₹8.61 Cr | ₹2.7 Cr | -₹7.3 Cr | -₹25.21 Cr | -₹5.01 Cr | -₹5.98 Cr |
| Employee Benefit Expense | ₹141.48 Cr | ₹126.14 Cr | ₹132.15 Cr | ₹117.06 Cr | ₹99.97 Cr | ₹94.66 Cr | ₹95.9 Cr |
| Finance Costs | ₹89 Lakh | ₹62 Lakh | ₹45 Lakh | ₹31 Lakh | ₹52 Lakh | ₹79 Lakh | ₹1.75 Cr |
| Depreciation & Amortisation | ₹21.48 Cr | ₹21.43 Cr | ₹17.07 Cr | ₹15.5 Cr | ₹15.66 Cr | ₹16.47 Cr | ₹16.36 Cr |
| Other Expenses | ₹166.82 Cr | ₹153.63 Cr | ₹137.22 Cr | ₹122.19 Cr | ₹112.01 Cr | ₹93.45 Cr | ₹92.76 Cr |
| Total Expenses | ₹582.76 Cr | ₹515.83 Cr | ₹471.42 Cr | ₹425.93 Cr | ₹369.98 Cr | ₹336.47 Cr | ₹334.53 Cr |
| Profit Before Exceptional Items & Tax | ₹150.3 Cr | ₹150.28 Cr | ₹117.84 Cr | ₹91.68 Cr | ₹73.17 Cr | ₹53.58 Cr | ₹41.77 Cr |
| Exceptional Items | ₹3.9 Cr | ₹82.6 Cr | ₹0 | ₹0 | ₹0 | ₹0 | -₹5.32 Cr |
| Profit Before Tax | ₹154.2 Cr | ₹232.88 Cr | ₹117.84 Cr | ₹91.68 Cr | ₹73.17 Cr | ₹53.58 Cr | ₹36.45 Cr |
| Total Tax Expense | ₹39.03 Cr | ₹49.64 Cr | ₹30.18 Cr | ₹24.04 Cr | ₹21.69 Cr | ₹13.58 Cr | ₹7.44 Cr |
| Net Profit | ₹115.17 Cr | ₹183.24 Cr | ₹87.66 Cr | ₹67.64 Cr | ₹51.48 Cr | ₹40 Cr | ₹29.01 Cr |
| Other Comprehensive Income | -₹64 Lakh | -₹1.1 Cr | -₹56 Lakh | ₹7 Lakh | -₹25 Lakh | -₹12 Lakh | -₹17 Lakh |
| Total Comprehensive Income | ₹114.53 Cr | ₹182.14 Cr | ₹87.1 Cr | ₹67.71 Cr | ₹51.23 Cr | ₹39.88 Cr | ₹28.84 Cr |
| EBITDA (computed) | ₹172.67 Cr | ₹172.33 Cr | ₹135.36 Cr | ₹107.49 Cr | ₹89.35 Cr | ₹70.84 Cr | ₹59.88 Cr |
| Basic EPS | ₹69.64 | ₹110.80 | ₹53.01 | ₹40.90 | ₹31.13 | ₹24.19 | ₹17.54 |
| Diluted EPS | ₹0.00 | ₹0.00 | ₹53.01 | ₹40.90 | ₹31.13 | ₹24.19 | ₹17.54 |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Total Assets | ₹793.15 Cr | ₹657.81 Cr | ₹512.87 Cr | ₹419.35 Cr |
| Non-current Assets | ₹263.19 Cr | ₹191 Cr | ₹213.56 Cr | ₹153.57 Cr |
| Current Assets | ₹529.96 Cr | ₹466.81 Cr | ₹299.31 Cr | ₹265.78 Cr |
| Property, Plant & Equipment | ₹191.7 Cr | ₹161.18 Cr | ₹97.03 Cr | ₹101.27 Cr |
| Inventories | ₹123.84 Cr | ₹92.98 Cr | ₹101 Cr | ₹95.05 Cr |
| Trade Receivables | ₹116.68 Cr | ₹86.76 Cr | ₹49.13 Cr | ₹37.43 Cr |
| Cash & Equivalents | ₹115.68 Cr | ₹28.7 Cr | ₹19.72 Cr | ₹24.82 Cr |
| Equity (Net Worth) | ₹605.38 Cr | ₹530.53 Cr | ₹374.85 Cr | ₹307.6 Cr |
| Equity Share Capital | ₹13.23 Cr | ₹13.23 Cr | ₹13.23 Cr | ₹13.23 Cr |
| Borrowings (Non-current) | ₹13.33 Cr | ₹0 | ₹0 | ₹0 |
| Borrowings (Current) | ₹6.67 Cr | ₹0 | ₹0 | ₹1 Lakh |
| Total Debt (computed) | ₹20 Cr | ₹0 | ₹0 | ₹1 Lakh |
| Current Liabilities | ₹160.53 Cr | ₹119.83 Cr | ₹130.96 Cr | ₹102.78 Cr |
| Total Liabilities | ₹187.77 Cr | ₹127.28 Cr | ₹138.02 Cr | ₹111.75 Cr |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Operating Cash Flow | ₹56.5 Cr | ₹77.86 Cr | ₹94.36 Cr | ₹90.82 Cr | ₹64.75 Cr |
| Investing Cash Flow | ₹51.06 Cr | -₹41.8 Cr | -₹79.15 Cr | -₹105.82 Cr | -₹34.66 Cr |
| Financing Cash Flow | -₹20.58 Cr | -₹27.08 Cr | -₹20.31 Cr | -₹17.12 Cr | -₹13.51 Cr |
| Capital Expenditure | ₹65.36 Cr | ₹36.03 Cr | ₹69.23 Cr | ₹32.74 Cr | ₹23.95 Cr |
| Free Cash Flow (computed) | -₹8.86 Cr | ₹41.83 Cr | ₹25.13 Cr | ₹58.08 Cr | ₹40.8 Cr |
| Dividends Paid | ₹39.69 Cr | ₹26.46 Cr | ₹19.85 Cr | ₹15.88 Cr | ₹11.91 Cr |
| Net Change in Cash | ₹86.98 Cr | ₹8.98 Cr | -₹5.1 Cr | -₹32.12 Cr | ₹16.58 Cr |
| Metrics | Q4 FY26 | Q3 FY26 | Q2 FY26 | Q1 FY26 | Q4 FY25 | Q3 FY25 | Q2 FY25 | Q1 FY25 | Q4 FY24 | Q3 FY24 | Q2 FY24 | Q1 FY24 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹176.89 Cr | ₹180.03 Cr | ₹181.68 Cr | ₹168.92 Cr | ₹143.09 Cr | ₹172.71 Cr | ₹172.21 Cr | ₹165.42 Cr | ₹126.99 Cr | ₹153.7 Cr | ₹153.58 Cr | ₹147.78 Cr |
| Other Income | ₹12.36 Cr | ₹3.41 Cr | ₹4.54 Cr | ₹5.23 Cr | ₹5.06 Cr | ₹3.31 Cr | ₹1.94 Cr | ₹2.37 Cr | ₹1.65 Cr | ₹1.92 Cr | ₹1.83 Cr | ₹1.81 Cr |
| Total Income | ₹189.25 Cr | ₹183.44 Cr | ₹186.22 Cr | ₹174.15 Cr | ₹148.15 Cr | ₹176.02 Cr | ₹174.15 Cr | ₹167.79 Cr | ₹128.64 Cr | ₹155.62 Cr | ₹155.41 Cr | ₹149.59 Cr |
| Cost of Materials Consumed | ₹36.43 Cr | ₹34.79 Cr | ₹32.72 Cr | ₹32.04 Cr | ₹26.89 Cr | ₹30.19 Cr | ₹20.81 Cr | ₹32.37 Cr | ₹28.03 Cr | ₹24.85 Cr | ₹37.3 Cr | ₹30.47 Cr |
| Purchases of Stock-in-Trade | ₹22.63 Cr | ₹43.63 Cr | ₹38.78 Cr | ₹33.06 Cr | ₹21.22 Cr | ₹22.7 Cr | ₹26.33 Cr | ₹24.89 Cr | ₹14.92 Cr | ₹16.49 Cr | ₹13.11 Cr | ₹16.66 Cr |
| Changes in Inventories | ₹1.53 Cr | -₹13.52 Cr | -₹4.92 Cr | -₹5.08 Cr | ₹61 Lakh | ₹3.22 Cr | ₹7.03 Cr | -₹2.25 Cr | -₹1.51 Cr | ₹6.83 Cr | -₹5.67 Cr | ₹3.05 Cr |
| Employee Benefit Expense | ₹36.3 Cr | ₹35.32 Cr | ₹36.16 Cr | ₹33.7 Cr | ₹31.6 Cr | ₹28.71 Cr | ₹33.09 Cr | ₹32.74 Cr | ₹32.08 Cr | ₹33.69 Cr | ₹33.59 Cr | ₹32.79 Cr |
| Finance Costs | ₹39 Lakh | ₹25 Lakh | ₹12 Lakh | ₹13 Lakh | ₹18 Lakh | ₹12 Lakh | ₹17 Lakh | ₹15 Lakh | ₹14 Lakh | ₹14 Lakh | ₹10 Lakh | ₹7 Lakh |
| Depreciation & Amortisation | ₹5.74 Cr | ₹5.38 Cr | ₹5.22 Cr | ₹5.14 Cr | ₹5.37 Cr | ₹5.46 Cr | ₹5.31 Cr | ₹5.29 Cr | ₹4.49 Cr | ₹4.14 Cr | ₹4.23 Cr | ₹4.21 Cr |
| Other Expenses | ₹47.13 Cr | ₹40.05 Cr | ₹39.91 Cr | ₹39.73 Cr | ₹37.28 Cr | ₹38.73 Cr | ₹39.02 Cr | ₹38.6 Cr | ₹32.75 Cr | ₹33.94 Cr | ₹37.96 Cr | ₹32.57 Cr |
| Total Expenses | ₹150.15 Cr | ₹145.9 Cr | ₹147.99 Cr | ₹138.72 Cr | ₹123.15 Cr | ₹129.13 Cr | ₹131.76 Cr | ₹131.79 Cr | ₹110.9 Cr | ₹120.08 Cr | ₹120.62 Cr | ₹119.82 Cr |
| Profit Before Exceptional Items & Tax | ₹39.1 Cr | ₹37.54 Cr | ₹38.23 Cr | ₹35.43 Cr | ₹25 Cr | ₹46.89 Cr | ₹42.39 Cr | ₹36 Cr | ₹17.74 Cr | ₹35.54 Cr | ₹34.79 Cr | ₹29.77 Cr |
| Exceptional Items | ₹1.1 Cr | -₹8.42 Cr | ₹11.22 Cr | ₹0 | ₹109.9 Cr | ₹0 | -₹27.3 Cr | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Profit Before Tax | ₹40.2 Cr | ₹29.12 Cr | ₹49.45 Cr | ₹35.43 Cr | ₹134.9 Cr | ₹46.89 Cr | ₹15.09 Cr | ₹36 Cr | ₹17.74 Cr | ₹35.54 Cr | ₹34.79 Cr | ₹29.77 Cr |
| Total Tax Expense | ₹10.3 Cr | ₹6.99 Cr | ₹12.6 Cr | ₹9.14 Cr | ₹17.55 Cr | ₹11.96 Cr | ₹10.89 Cr | ₹9.24 Cr | ₹4.5 Cr | ₹9.08 Cr | ₹8.93 Cr | ₹7.67 Cr |
| Net Profit | ₹29.9 Cr | ₹22.13 Cr | ₹36.85 Cr | ₹26.29 Cr | ₹117.35 Cr | ₹34.93 Cr | ₹4.2 Cr | ₹26.76 Cr | ₹13.24 Cr | ₹26.46 Cr | ₹25.86 Cr | ₹22.1 Cr |
| Other Comprehensive Income | ₹8 Lakh | -₹68 Lakh | -₹2 Lakh | -₹1 Lakh | -₹1.15 Cr | ₹1 Lakh | ₹2 Lakh | ₹1 Lakh | -₹60 Lakh | ₹1 Lakh | ₹2 Lakh | ₹1 Lakh |
| Total Comprehensive Income | ₹29.98 Cr | ₹21.45 Cr | ₹36.83 Cr | ₹26.28 Cr | ₹116.2 Cr | ₹34.94 Cr | ₹4.22 Cr | ₹26.77 Cr | ₹12.64 Cr | ₹26.47 Cr | ₹25.88 Cr | ₹22.11 Cr |
| EBITDA (computed) | ₹45.23 Cr | ₹43.17 Cr | ₹43.57 Cr | ₹40.7 Cr | ₹30.55 Cr | ₹52.47 Cr | ₹47.87 Cr | ₹41.44 Cr | ₹22.37 Cr | ₹39.82 Cr | ₹39.12 Cr | ₹34.05 Cr |
| Basic EPS | ₹18.08 | ₹13.38 | ₹22.28 | ₹15.90 | ₹70.96 | ₹21.12 | ₹2.54 | ₹16.18 | ₹8.01 | ₹16.00 | ₹15.64 | ₹13.36 |
| Diluted EPS | ₹0.00 | ₹0.00 | ₹0.00 | ₹0.00 | ₹0.00 | ₹21.12 | ₹2.54 | ₹16.18 | ₹8.01 | ₹16.00 | ₹15.64 | ₹13.36 |
Shareholding Pattern of Rpg Life Sciences Limited
As per the shareholding pattern filed with NSE for the quarter ended Mar 2026, promoters hold 72.95%, foreign institutional investors hold 0.87%, domestic institutional investors hold 7.45%, retail and other public shareholders hold 18.73% of Rpg Life Sciences Limited. The company had 25,282 shareholders on record.
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | |
|---|---|---|---|---|---|---|
| Promoters | 72.95% | 72.95% | 72.95% | 72.95% | 72.95% | 72.95% |
| Public | 27.05% | 27.05% | 27.05% | 27.05% | 27.05% | 27.05% |
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoters | 72.95% | 72.95% | 72.81% | 72.81% | 72.07% | 72.07% | 72.07% | 70.99% | 69.22% | 67.48% | 66.79% |
| Public | 27.05% | 27.05% | 27.19% | 27.19% | 27.93% | 27.93% | 27.92% | 29.01% | 30.78% | 32.52% | 33.21% |
| Promoter change (YoY, %pts) | +0.00 | +0.14 | +0.00 | +0.74 | +0.00 | +0.00 | +1.08 | +1.77 | +1.74 | +0.69 | - |
Board & Governance of Rpg Life Sciences Limited
As per the corporate governance filing with NSE for the quarter ended 31-MAR-2026, the board of Rpg Life Sciences Limited has 12 directors - 6 independent and 1 executive. The board is chaired by Harsh V. Goenka.
| Director | Position | On board since | Listed boards |
|---|---|---|---|
| Harsh V. Goenka | Non-Executive - Non Independent Director · Chairperson | 2008-02-06 | 4 |
| Vasundhara Patni | Non-Executive - Non Independent Director | 2025-04-28 | 0 |
| Manoj Maheshwari | Non-Executive - Non Independent Director | 2024-09-25 | 2 |
| Sachin R. Nandgaonkar | Non-Executive - Independent Director | 2024-04-30 | 2 |
| Zahabiya Khorakiwala | Non-Executive - Independent Director | 2016-07-27 | 2 |
| Bhaskar Iyer | Non-Executive - Independent Director | 2019-10-30 | 2 |
| Anil Matai | Non-Executive - Independent Director | 2024-04-30 | 1 |
| Hiten Kotak | Non-Executive - Independent Director | 2024-04-30 | 1 |
| Radhika Gupta | Non-Executive - Independent Director | 2024-04-30 | 1 |
| Rajat Bhargava | Non-Executive - Non Independent Director | 2021-01-25 | 2 |
| Yugal Sikri | Non-Executive - Non Independent Director | 2025-05-01 | 1 |
| Ashok Nair | Executive Director · MD | 2025-05-01 | 1 |
| Committee | Members |
|---|---|
| Audit Committee | Hiten Kotak (Chairperson), Bhaskar Iyer, Anil Matai, Rajat Bhargava |
| Nomination and remuneration committee | Bhaskar Iyer (Chairperson), Rajat Bhargava, Sachin R. Nandgaonkar, Radhika Gupta |
| Stakeholders Relationship Committee | Radhika Gupta (Chairperson), Anil Matai, Ashok Nair |
| Risk Management Committee | Anil Matai (Chairperson), Rajat Bhargava, Bhaskar Iyer, Hiten Kotak |
| Corporate Social Responsibility Committee | Radhika Gupta (Chairperson), Zahabiya Khorakiwala, Ashok Nair, Sachin R. Nandgaonkar |
Charges & Borrowings of Rpg Life Sciences Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 12 Sep 2009 | Others | ₹65.92 Cr | Open |
| 12 Apr 2017 | Others | ₹20 Cr | Satisfied |
| 25 Jan 2012 | Export Import Bank of India | ₹7.55 Cr | Satisfied |
| 28 Jan 2011 | Export-Import Bank of India | ₹7 Cr | Satisfied |
| 14 Jul 2010 | Export Import Bank of India | ₹3.4 Cr | Satisfied |
Total charge records: 10 View all charges
Employees and EPFO Compliance at Rpg Life Sciences Limited
Rpg Life Sciences Limited has a workforce of 1,197 employees as of Apr 01, 2024.
Employee Count & EPFO Data of Rpg Life Sciences Limited
Access employee headcount trends, monthly PF payment records, EPFO establishment details, and compliance data.
GST Compliance of Rpg Life Sciences Limited
GSTIN & GST Filing Data of Rpg Life Sciences Limited
Access GSTIN registrations, state-wise filing compliance, HSN/SAC codes, and detailed goods & services data.
Credit Ratings, Litigation & Regulatory Alerts for Rpg Life Sciences Limited
Credit Ratings, Legal Cases & Regulatory Alerts of Rpg Life Sciences Limited
Access complete credit rating history, litigation records, regulatory alerts, and compliance data.
MSME Payment Delays by Rpg Life Sciences Limited
MSME Payment Delays by Rpg Life Sciences Limited
Track payments outstanding to micro and small enterprise vendors, as disclosed in half-yearly MSME-1 returns filed with the MCA.
Subsidiaries & Group Companies of Rpg Life Sciences Limited
Subsidiaries & Group Companies of Rpg Life Sciences Limited
See the full corporate group - holding company, subsidiaries, associates and joint ventures of Rpg Life Sciences Limited with ownership details.
MCA Filings & Documents of Rpg Life Sciences Limited
MCA Filings & Documents of Rpg Life Sciences Limited
Download official documents filed with the Ministry of Corporate Affairs - from incorporation papers to the latest annual filings.
Recent Activity on Rpg Life Sciences Limited
Recent News on Rpg Life Sciences Limited
Frequently Asked Questions about Rpg Life Sciences Limited
Rpg Life Sciences Limited is an active public limited company in the pharma sector based in Mumbai, Maharashtra, India. It was incorporated on 29 March 2007 (19+ years old) and is registered under CIN L24232MH2007PLC169354. Listed on BSE: 532983 and NSE: RPGLIFE. The company has 1,197 employees.
Rpg Life Sciences Limited reported revenue of ₹666.11 Cr for FY 2025 (up 13.00% YoY).
The current directors of Rpg Life Sciences Limited are:
- Sachin Rajkumar Nandgaonkar
- Vasundhara Apoorva Patni
- Vishal Dilip Shah
- Rajesh Ramesh Shirambekar
- Hiten Kantilal Kotak
- Anilkumar Matai
- Rajat Bhargava
- Ashok Nair
- Manojkumar Madangopal Maheshwari
- Yugal Kishor Chothuram Sikri
- Radhika Gupta
- Harsh Vardhan Goenka
- Zahabiya Habil Khorakiwala
- Bhaskar Vemban Iyer
- Amol Narayan Lone
The primary industry of Rpg Life Sciences Limited is pharma. The company specifically operates in api manufacturers. The company is currently active in this sector.
Yes. Rpg Life Sciences Limited is listed on both BSE (code: 532983) and NSE (symbol: RPGLIFE).
Rpg Life Sciences Limited can be reached at the registered office: Rpg House 463 Dr. Annie Besant Road Worli, Mumbai, Maharashtra, India – 400030, or through the website rpglifesciences.com.